Form 6-K InflaRx N.V. For: Sep 29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission File Number: 001-38283
InflaRx N.V.
(Translation of registrant's name into English)
Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFLARX N.V.
On September 29, 2022, InflaRx N.V. issued a press release titled “InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients.” A copy of the
press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INFLARX N.V.
|
|||
Date: September 29, 2022
|
By:
|
/s/ Niels Riedemann
|
|
Name:
|
Niels Riedemann
|
||
Title:
|
Chief Executive Officer
|
3
EXHIBIT INDEX
Exhibit No.
|
Description
|
|
Press Release, dated September 29, 2022
|
4
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BrightView Partners with Red Wing Shoes to Equip 18,000 Team Members with Safety Boots
- Sprouts Farmers Market Announces New NIL Deals
- Viridi Energy Acquires Maine Digester Facility for Industry-Leading Biosolids-to-RNG Project
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!